ABIN250389

antibody from antibodies-online

Targeting: AKAP9 AKAP350, AKAP450, CG-NAP, HYPERION, KIAA0803, LQT11, MU-RMS-40.16A, PPP1R45, PRKA9, YOTIAO

Western blot (Recommended by provider)

ELISA (Recommended by provider)

Immunohistochemistry (Recommended by provider)

Antibody Data

Product number

ABIN250389

Provider

antibodies-online

Product name

anti-A Kinase (PRKA) Anchor Protein (Yotiao) 9 (AKAP9) (C-Term) antibody

Antibody type

Polyclonal

Description

Immunogen affinity purified

Reactivity

Human, Rat

Host

Goat

Epitope

C-Term

Vial size

0.1 mg

Storage

Store at -20°C. Avoid freeze-thaw cycles.

Handling

Avoid freeze-thaw cycles

References

Submitted references

Small molecule AKAP-protein kinase A (PKA) interaction disruptors that activate PKA interfere with compartmentalized cAMP signaling in cardiac myocytes.

Christian F, Szaszák M, Friedl S, Drewianka S, Lorenz D, Goncalves A, Furkert J, Vargas C, Schmieder P, Götz F, Zühlke K, Moutty M, Göttert H, Joshi M, Reif B, Haase H, Morano I, Grossmann S, Klukovits A, Verli J, Gáspár R, Noack C, Bergmann M, Kass R, Hampel K, Kashin D, Genieser HG, Herberg FW, Willoughby D, Cooper DM, Baillie GS, Houslay MD, von Kries JP, Zimmermann B, Rosenthal W, Klussmann E
The Journal of biological chemistry 2011 Mar 18;286(11):9079-96

---

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.

Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE
The Journal of clinical investigation 2005 Jan;115(1):94-101